secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001437749-22-019840
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica identifies cause of DM199 clinical hold; plans FDA resubmission in Sep
--------------------------------------------------------------------------------

- Clinical hold cause: DM199 protein bound to prior IV bag, reducing dose; new bag delivered higher dose, causing hypotension.
- Will submit revised protocol to FDA in September requesting removal of clinical hold; FDA has 30 days to respond.
- Cash and investments $38.4M as of June 30, 2022; cash runway into 2024.
- R&D expenses $2.0M in Q2 2022 vs $2.2M Q2 2021; net cash used in ops $6.4M for six months.
- REDUX CKD trial close-out ongoing; company maintains focus on acute ischemic stroke program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774922019840/0001437749-22-019840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774922019840/dmtp20220810_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-019840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer